| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 411 | 2023 | 2032 | 37.460 |
Why?
|
| Anti-Asthmatic Agents | 126 | 2023 | 349 | 21.450 |
Why?
|
| Adrenal Cortex Hormones | 67 | 2023 | 498 | 9.230 |
Why?
|
| Bronchodilator Agents | 57 | 2023 | 240 | 7.740 |
Why?
|
| Glucocorticoids | 69 | 2019 | 532 | 4.970 |
Why?
|
| Administration, Inhalation | 107 | 2023 | 642 | 4.480 |
Why?
|
| Tiotropium Bromide | 14 | 2019 | 18 | 4.330 |
Why?
|
| Child | 241 | 2023 | 18352 | 3.780 |
Why?
|
| Adrenergic beta-Agonists | 26 | 2018 | 125 | 3.460 |
Why?
|
| Budesonide | 32 | 2016 | 87 | 3.200 |
Why?
|
| School Health Services | 10 | 2018 | 206 | 3.110 |
Why?
|
| Biological Products | 7 | 2023 | 167 | 2.960 |
Why?
|
| Respiratory Sounds | 17 | 2019 | 111 | 2.940 |
Why?
|
| Nebulizers and Vaporizers | 22 | 2023 | 78 | 2.900 |
Why?
|
| Albuterol | 34 | 2018 | 102 | 2.810 |
Why?
|
| Humans | 463 | 2023 | 114757 | 2.800 |
Why?
|
| Acetates | 22 | 2014 | 95 | 2.760 |
Why?
|
| Quinolines | 22 | 2014 | 129 | 2.670 |
Why?
|
| Anti-Inflammatory Agents | 32 | 2019 | 450 | 2.640 |
Why?
|
| Androstadienes | 29 | 2020 | 97 | 2.630 |
Why?
|
| Cholinergic Antagonists | 8 | 2019 | 27 | 2.600 |
Why?
|
| Urban Population | 12 | 2019 | 398 | 2.380 |
Why?
|
| Leukotriene Antagonists | 21 | 2020 | 41 | 2.370 |
Why?
|
| Practice Guidelines as Topic | 27 | 2020 | 1393 | 2.230 |
Why?
|
| Nitric Oxide | 25 | 2020 | 824 | 2.200 |
Why?
|
| Omalizumab | 12 | 2021 | 45 | 2.190 |
Why?
|
| Adolescent | 147 | 2023 | 17808 | 2.150 |
Why?
|
| Theophylline | 27 | 2018 | 60 | 2.140 |
Why?
|
| Disease Progression | 41 | 2023 | 2387 | 2.140 |
Why?
|
| Precision Medicine | 14 | 2021 | 338 | 2.130 |
Why?
|
| Forced Expiratory Volume | 54 | 2023 | 476 | 1.900 |
Why?
|
| Fluticasone | 34 | 2021 | 87 | 1.770 |
Why?
|
| Child, Preschool | 97 | 2020 | 9079 | 1.750 |
Why?
|
| Social Determinants of Health | 5 | 2022 | 135 | 1.640 |
Why?
|
| Double-Blind Method | 60 | 2021 | 1662 | 1.580 |
Why?
|
| Severity of Illness Index | 36 | 2023 | 2539 | 1.550 |
Why?
|
| Biomarkers | 34 | 2021 | 3416 | 1.500 |
Why?
|
| Medication Adherence | 14 | 2023 | 537 | 1.490 |
Why?
|
| Treatment Outcome | 67 | 2023 | 9089 | 1.480 |
Why?
|
| Hypersensitivity | 8 | 2020 | 254 | 1.450 |
Why?
|
| Male | 225 | 2023 | 55579 | 1.380 |
Why?
|
| Female | 222 | 2023 | 59507 | 1.360 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 9 | 2019 | 32 | 1.280 |
Why?
|
| Schools | 8 | 2022 | 399 | 1.230 |
Why?
|
| Clinical Trials as Topic | 18 | 2020 | 935 | 1.230 |
Why?
|
| Antibodies, Anti-Idiotypic | 6 | 2014 | 54 | 1.230 |
Why?
|
| Beclomethasone | 18 | 2015 | 25 | 1.200 |
Why?
|
| Health Status Disparities | 3 | 2020 | 201 | 1.200 |
Why?
|
| Adult | 117 | 2023 | 30548 | 1.180 |
Why?
|
| Anti-Allergic Agents | 5 | 2017 | 41 | 1.170 |
Why?
|
| Drug Therapy, Combination | 28 | 2022 | 954 | 1.170 |
Why?
|
| Breath Tests | 11 | 2020 | 82 | 1.150 |
Why?
|
| Mobile Applications | 2 | 2020 | 140 | 1.140 |
Why?
|
| Betacoronavirus | 2 | 2020 | 252 | 1.120 |
Why?
|
| School Nursing | 2 | 2018 | 24 | 1.110 |
Why?
|
| Disease Management | 14 | 2019 | 560 | 1.110 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 4 | 2023 | 242 | 1.020 |
Why?
|
| Respiratory Function Tests | 40 | 2021 | 524 | 1.000 |
Why?
|
| Healthcare Disparities | 4 | 2019 | 479 | 1.000 |
Why?
|
| Global Health | 4 | 2020 | 288 | 0.980 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 340 | 0.980 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 332 | 0.970 |
Why?
|
| Antibodies, Monoclonal, Humanized | 6 | 2023 | 664 | 0.970 |
Why?
|
| Receptors, Glucocorticoid | 20 | 2011 | 130 | 0.960 |
Why?
|
| Immunoglobulin E | 20 | 2019 | 316 | 0.940 |
Why?
|
| Exhalation | 10 | 2020 | 35 | 0.930 |
Why?
|
| Drug Administration Schedule | 24 | 2019 | 718 | 0.920 |
Why?
|
| Cyclopropanes | 23 | 2014 | 81 | 0.910 |
Why?
|
| Pharmacology, Clinical | 1 | 2023 | 8 | 0.900 |
Why?
|
| Pituitary-Adrenal System | 4 | 2016 | 131 | 0.890 |
Why?
|
| Hypothalamo-Hypophyseal System | 4 | 2016 | 165 | 0.880 |
Why?
|
| Lung | 23 | 2023 | 3546 | 0.870 |
Why?
|
| Allergy and Immunology | 3 | 2019 | 51 | 0.870 |
Why?
|
| Prednisone | 22 | 2019 | 231 | 0.870 |
Why?
|
| Biological Therapy | 3 | 2023 | 27 | 0.870 |
Why?
|
| Sulfides | 22 | 2014 | 94 | 0.850 |
Why?
|
| Eosinophils | 14 | 2019 | 278 | 0.800 |
Why?
|
| Monitoring, Physiologic | 12 | 2020 | 248 | 0.800 |
Why?
|
| Salmeterol Xinafoate | 19 | 2021 | 41 | 0.790 |
Why?
|
| Drug Resistance | 21 | 2008 | 158 | 0.780 |
Why?
|
| Self Report | 4 | 2021 | 695 | 0.780 |
Why?
|
| Randomized Controlled Trials as Topic | 17 | 2021 | 1214 | 0.780 |
Why?
|
| Nonprescription Drugs | 1 | 2022 | 68 | 0.770 |
Why?
|
| Allergens | 14 | 2021 | 413 | 0.770 |
Why?
|
| Child Health | 2 | 2020 | 126 | 0.760 |
Why?
|
| Health Equity | 1 | 2022 | 53 | 0.760 |
Why?
|
| Scopolamine Derivatives | 4 | 2017 | 6 | 0.760 |
Why?
|
| Poverty | 4 | 2022 | 442 | 0.760 |
Why?
|
| Methylprednisolone | 19 | 1999 | 82 | 0.750 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 6 | 2023 | 916 | 0.750 |
Why?
|
| Risk Adjustment | 1 | 2021 | 75 | 0.730 |
Why?
|
| Communicable Disease Control | 1 | 2021 | 67 | 0.730 |
Why?
|
| Cross-Over Studies | 18 | 2019 | 440 | 0.720 |
Why?
|
| Risk Factors | 24 | 2020 | 8627 | 0.720 |
Why?
|
| Medication Therapy Management | 1 | 2021 | 67 | 0.710 |
Why?
|
| Symptom Flare Up | 2 | 2019 | 38 | 0.680 |
Why?
|
| Motivation | 1 | 2023 | 494 | 0.650 |
Why?
|
| Program Development | 2 | 2018 | 342 | 0.650 |
Why?
|
| Phenotype | 17 | 2021 | 2812 | 0.640 |
Why?
|
| Bronchial Hyperreactivity | 7 | 2015 | 95 | 0.640 |
Why?
|
| Nedocromil | 9 | 2016 | 32 | 0.640 |
Why?
|
| Drug Monitoring | 7 | 2019 | 184 | 0.640 |
Why?
|
| Troleandomycin | 13 | 1993 | 13 | 0.640 |
Why?
|
| Pandemics | 4 | 2022 | 1319 | 0.630 |
Why?
|
| Education, Medical, Continuing | 1 | 2020 | 118 | 0.630 |
Why?
|
| Guidelines as Topic | 7 | 2012 | 244 | 0.630 |
Why?
|
| Absenteeism | 2 | 2018 | 40 | 0.620 |
Why?
|
| Population | 1 | 2018 | 28 | 0.620 |
Why?
|
| Data Accuracy | 1 | 2018 | 48 | 0.610 |
Why?
|
| Prednisolone | 15 | 2011 | 75 | 0.610 |
Why?
|
| Vital Capacity | 13 | 2019 | 256 | 0.610 |
Why?
|
| Biomedical Research | 3 | 2012 | 585 | 0.590 |
Why?
|
| United States | 27 | 2021 | 12176 | 0.560 |
Why?
|
| Genome-Wide Association Study | 13 | 2016 | 1197 | 0.550 |
Why?
|
| Spirometry | 19 | 2021 | 225 | 0.540 |
Why?
|
| Age Factors | 20 | 2019 | 2890 | 0.540 |
Why?
|
| Lung Diseases | 2 | 2022 | 696 | 0.530 |
Why?
|
| United States Food and Drug Administration | 3 | 2009 | 172 | 0.530 |
Why?
|
| Reminder Systems | 1 | 2018 | 162 | 0.530 |
Why?
|
| Health Services Accessibility | 5 | 2019 | 763 | 0.530 |
Why?
|
| Pediatrics | 7 | 2019 | 983 | 0.520 |
Why?
|
| Eye | 1 | 2016 | 101 | 0.520 |
Why?
|
| Th2 Cells | 2 | 2017 | 154 | 0.520 |
Why?
|
| Polymorphism, Single Nucleotide | 14 | 2016 | 1892 | 0.520 |
Why?
|
| Sputum | 7 | 2019 | 285 | 0.510 |
Why?
|
| Leukocyte Count | 11 | 2019 | 292 | 0.510 |
Why?
|
| Telemedicine | 3 | 2020 | 663 | 0.500 |
Why?
|
| Research Design | 9 | 2023 | 931 | 0.490 |
Why?
|
| Health Personnel | 3 | 2017 | 574 | 0.490 |
Why?
|
| Evidence-Based Practice | 2 | 2018 | 185 | 0.490 |
Why?
|
| Drug Labeling | 2 | 2006 | 42 | 0.480 |
Why?
|
| Self-Management | 1 | 2016 | 126 | 0.470 |
Why?
|
| Medicaid | 1 | 2018 | 407 | 0.470 |
Why?
|
| Epigenesis, Genetic | 4 | 2016 | 521 | 0.460 |
Why?
|
| Hypertension | 1 | 2022 | 1059 | 0.460 |
Why?
|
| Program Evaluation | 1 | 2018 | 822 | 0.460 |
Why?
|
| Eczema | 2 | 2014 | 81 | 0.450 |
Why?
|
| Administration, Oral | 19 | 2018 | 731 | 0.450 |
Why?
|
| Electronics | 4 | 2021 | 67 | 0.450 |
Why?
|
| Patient Compliance | 8 | 2019 | 525 | 0.450 |
Why?
|
| Middle Aged | 52 | 2021 | 26757 | 0.440 |
Why?
|
| Pharmacogenetics | 5 | 2015 | 149 | 0.440 |
Why?
|
| Environmental Exposure | 6 | 2019 | 374 | 0.430 |
Why?
|
| Prognosis | 15 | 2020 | 3334 | 0.430 |
Why?
|
| Immunotherapy | 1 | 2017 | 475 | 0.430 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 680 | 0.420 |
Why?
|
| Hydrocortisone | 15 | 2005 | 269 | 0.420 |
Why?
|
| Dexamethasone | 8 | 2019 | 317 | 0.410 |
Why?
|
| Infant | 28 | 2019 | 7935 | 0.410 |
Why?
|
| Virus Diseases | 3 | 2021 | 195 | 0.410 |
Why?
|
| Drug Interactions | 8 | 2023 | 340 | 0.390 |
Why?
|
| Macrolides | 1 | 2012 | 56 | 0.390 |
Why?
|
| Risk | 7 | 2018 | 815 | 0.390 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2015 | 452 | 0.390 |
Why?
|
| Triamcinolone Acetonide | 8 | 2003 | 27 | 0.390 |
Why?
|
| Triamcinolone | 5 | 2019 | 13 | 0.380 |
Why?
|
| Dose-Response Relationship, Drug | 23 | 2019 | 1846 | 0.370 |
Why?
|
| Product Surveillance, Postmarketing | 3 | 2016 | 63 | 0.370 |
Why?
|
| Pregnancy Complications | 3 | 2011 | 429 | 0.370 |
Why?
|
| Sleep Wake Disorders | 1 | 2014 | 233 | 0.370 |
Why?
|
| National Institutes of Health (U.S.) | 3 | 2010 | 106 | 0.360 |
Why?
|
| Cost of Illness | 2 | 2020 | 254 | 0.360 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2012 | 384 | 0.360 |
Why?
|
| Primary Prevention | 1 | 2012 | 172 | 0.360 |
Why?
|
| Comorbidity | 3 | 2020 | 1449 | 0.360 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2010 | 28 | 0.350 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 3 | 2015 | 93 | 0.350 |
Why?
|
| Skin Neoplasms | 2 | 2014 | 761 | 0.350 |
Why?
|
| Health Promotion | 1 | 2016 | 686 | 0.340 |
Why?
|
| Docosahexaenoic Acids | 1 | 2010 | 69 | 0.340 |
Why?
|
| Respiratory Tract Diseases | 3 | 2022 | 139 | 0.330 |
Why?
|
| Asthma, Exercise-Induced | 1 | 2009 | 7 | 0.320 |
Why?
|
| Quality of Life | 11 | 2021 | 2358 | 0.320 |
Why?
|
| Pregnenediones | 4 | 2005 | 21 | 0.320 |
Why?
|
| Connecticut | 2 | 2018 | 21 | 0.320 |
Why?
|
| Ribonucleases | 6 | 2003 | 52 | 0.320 |
Why?
|
| Leukotriene E4 | 4 | 2013 | 27 | 0.310 |
Why?
|
| Follow-Up Studies | 15 | 2017 | 4420 | 0.310 |
Why?
|
| Methotrexate | 5 | 1992 | 227 | 0.310 |
Why?
|
| Ibuprofen | 2 | 2021 | 74 | 0.310 |
Why?
|
| Time Factors | 23 | 2019 | 6124 | 0.310 |
Why?
|
| Sleep | 4 | 2015 | 632 | 0.310 |
Why?
|
| Fluticasone-Salmeterol Drug Combination | 4 | 2016 | 12 | 0.310 |
Why?
|
| Seasons | 5 | 2019 | 450 | 0.310 |
Why?
|
| Early Diagnosis | 2 | 2019 | 216 | 0.300 |
Why?
|
| Predictive Value of Tests | 11 | 2020 | 1796 | 0.300 |
Why?
|
| Airway Obstruction | 6 | 2019 | 168 | 0.300 |
Why?
|
| Peak Expiratory Flow Rate | 12 | 2015 | 33 | 0.280 |
Why?
|
| Pulmonary Ventilation | 3 | 2005 | 74 | 0.280 |
Why?
|
| Respiratory Tract Infections | 4 | 2018 | 319 | 0.280 |
Why?
|
| Prevalence | 8 | 2020 | 2249 | 0.280 |
Why?
|
| Growth | 8 | 2006 | 56 | 0.280 |
Why?
|
| Environment | 3 | 2019 | 336 | 0.280 |
Why?
|
| Antibodies, Monoclonal | 2 | 2011 | 1270 | 0.270 |
Why?
|
| Antioxidants | 1 | 2010 | 530 | 0.270 |
Why?
|
| Hydrocarbons, Fluorinated | 3 | 2002 | 9 | 0.260 |
Why?
|
| Receptors, Adrenergic, beta-2 | 5 | 2015 | 39 | 0.260 |
Why?
|
| Research | 3 | 2016 | 394 | 0.260 |
Why?
|
| Occupational Exposure | 1 | 2009 | 255 | 0.260 |
Why?
|
| Drug Combinations | 6 | 2019 | 286 | 0.260 |
Why?
|
| Airway Resistance | 3 | 2020 | 30 | 0.260 |
Why?
|
| Bone Density | 5 | 2018 | 432 | 0.250 |
Why?
|
| Steroids | 6 | 2017 | 145 | 0.250 |
Why?
|
| Suspensions | 6 | 2012 | 30 | 0.250 |
Why?
|
| Hydroxycorticosteroids | 1 | 2005 | 1 | 0.250 |
Why?
|
| Rhinovirus | 3 | 2017 | 40 | 0.240 |
Why?
|
| Leukocytes, Mononuclear | 5 | 2015 | 493 | 0.240 |
Why?
|
| Cromolyn Sodium | 5 | 2002 | 13 | 0.240 |
Why?
|
| Animals | 23 | 2019 | 31762 | 0.240 |
Why?
|
| Cost-Benefit Analysis | 3 | 2019 | 545 | 0.240 |
Why?
|
| Delivery of Health Care | 3 | 2022 | 833 | 0.230 |
Why?
|
| Bronchoscopy | 6 | 2019 | 246 | 0.230 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2020 | 815 | 0.230 |
Why?
|
| Young Adult | 18 | 2023 | 10463 | 0.230 |
Why?
|
| Pulmonary Medicine | 1 | 2005 | 87 | 0.230 |
Why?
|
| Receptors, Adrenergic, beta | 4 | 2005 | 124 | 0.230 |
Why?
|
| Patient Education as Topic | 4 | 2014 | 679 | 0.220 |
Why?
|
| Colorado | 6 | 2018 | 4086 | 0.220 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2005 | 179 | 0.220 |
Why?
|
| Cohort Studies | 14 | 2017 | 4901 | 0.220 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2005 | 299 | 0.220 |
Why?
|
| Chlorofluorocarbons | 2 | 2002 | 2 | 0.220 |
Why?
|
| Administration, Topical | 7 | 2003 | 139 | 0.220 |
Why?
|
| Obesity | 6 | 2020 | 2513 | 0.220 |
Why?
|
| Mometasone Furoate | 2 | 2019 | 5 | 0.210 |
Why?
|
| Bronchiolitis, Viral | 1 | 2003 | 10 | 0.210 |
Why?
|
| Patient Dropouts | 1 | 2003 | 66 | 0.210 |
Why?
|
| Oscillometry | 3 | 2020 | 33 | 0.210 |
Why?
|
| Caregivers | 3 | 2019 | 717 | 0.210 |
Why?
|
| Diagnosis, Differential | 4 | 2020 | 1340 | 0.210 |
Why?
|
| Sex Factors | 9 | 2016 | 1717 | 0.210 |
Why?
|
| Self Care | 2 | 2016 | 350 | 0.210 |
Why?
|
| Treatment Failure | 9 | 2015 | 332 | 0.210 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2005 | 287 | 0.210 |
Why?
|
| Chronic Disease | 6 | 2020 | 1590 | 0.210 |
Why?
|
| Polymorphism, Genetic | 5 | 2009 | 612 | 0.200 |
Why?
|
| Anti-Bacterial Agents | 5 | 2015 | 1477 | 0.200 |
Why?
|
| T-Lymphocytes | 6 | 1999 | 1745 | 0.200 |
Why?
|
| Inflammation | 10 | 2021 | 2481 | 0.200 |
Why?
|
| Azithromycin | 2 | 2015 | 80 | 0.200 |
Why?
|
| Smoking | 4 | 2019 | 1384 | 0.190 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2003 | 98 | 0.190 |
Why?
|
| Genotype | 13 | 2015 | 1774 | 0.190 |
Why?
|
| Prospective Studies | 15 | 2019 | 6217 | 0.190 |
Why?
|
| Cross-Sectional Studies | 7 | 2020 | 4409 | 0.190 |
Why?
|
| Socioeconomic Factors | 5 | 2020 | 1078 | 0.190 |
Why?
|
| Pharmacogenomic Testing | 1 | 2021 | 53 | 0.190 |
Why?
|
| Feasibility Studies | 3 | 2020 | 737 | 0.180 |
Why?
|
| Half-Life | 16 | 2008 | 141 | 0.180 |
Why?
|
| Disease Transmission, Infectious | 1 | 2021 | 56 | 0.180 |
Why?
|
| Biological Availability | 13 | 2004 | 119 | 0.180 |
Why?
|
| Parents | 3 | 2018 | 1190 | 0.180 |
Why?
|
| Clarithromycin | 3 | 2010 | 25 | 0.180 |
Why?
|
| Morbidity | 2 | 2016 | 277 | 0.180 |
Why?
|
| Acetaminophen | 3 | 2021 | 238 | 0.180 |
Why?
|
| Residence Characteristics | 2 | 2020 | 275 | 0.180 |
Why?
|
| Bronchoconstriction | 4 | 2019 | 26 | 0.180 |
Why?
|
| Tobacco Smoke Pollution | 3 | 2010 | 217 | 0.180 |
Why?
|
| Hospitalization | 5 | 2019 | 1752 | 0.180 |
Why?
|
| Delayed-Action Preparations | 11 | 2016 | 159 | 0.180 |
Why?
|
| Growth Disorders | 2 | 2003 | 77 | 0.170 |
Why?
|
| Risk Assessment | 6 | 2021 | 2973 | 0.170 |
Why?
|
| Feedback | 1 | 2020 | 144 | 0.170 |
Why?
|
| Pregnancy | 7 | 2015 | 5525 | 0.170 |
Why?
|
| History, 21st Century | 2 | 2018 | 160 | 0.170 |
Why?
|
| Child Development | 5 | 2019 | 387 | 0.170 |
Why?
|
| History, 20th Century | 2 | 2018 | 265 | 0.170 |
Why?
|
| Respiratory Mechanics | 2 | 2015 | 56 | 0.170 |
Why?
|
| Circadian Rhythm | 6 | 1999 | 355 | 0.160 |
Why?
|
| Community Participation | 1 | 2020 | 116 | 0.160 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2018 | 18 | 0.160 |
Why?
|
| Body Height | 5 | 2013 | 180 | 0.160 |
Why?
|
| Risk Management | 1 | 2019 | 89 | 0.160 |
Why?
|
| Age of Onset | 3 | 2017 | 448 | 0.160 |
Why?
|
| Bronchi | 6 | 2012 | 232 | 0.160 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2014 | 965 | 0.160 |
Why?
|
| Patient Selection | 2 | 2021 | 641 | 0.160 |
Why?
|
| Administrative Claims, Healthcare | 1 | 2018 | 21 | 0.160 |
Why?
|
| Chromones | 1 | 1998 | 35 | 0.160 |
Why?
|
| Air Pollution | 2 | 2019 | 169 | 0.160 |
Why?
|
| Combined Modality Therapy | 4 | 2016 | 1122 | 0.160 |
Why?
|
| Prescription Drug Overuse | 1 | 2018 | 11 | 0.150 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2017 | 82 | 0.150 |
Why?
|
| Placebos | 5 | 2023 | 198 | 0.150 |
Why?
|
| Blood Cell Count | 1 | 2018 | 52 | 0.150 |
Why?
|
| Diagnostic Errors | 1 | 2019 | 148 | 0.150 |
Why?
|
| Case Management | 1 | 2018 | 62 | 0.150 |
Why?
|
| Cytokines | 2 | 2017 | 1843 | 0.150 |
Why?
|
| Microbiota | 2 | 2016 | 648 | 0.150 |
Why?
|
| Immunoglobulins, Intravenous | 3 | 1999 | 122 | 0.150 |
Why?
|
| Clinical Protocols | 4 | 2021 | 232 | 0.150 |
Why?
|
| Medication Errors | 1 | 2019 | 89 | 0.150 |
Why?
|
| Health Resources | 1 | 2019 | 122 | 0.150 |
Why?
|
| Community Networks | 1 | 2018 | 54 | 0.150 |
Why?
|
| Incidence | 4 | 2016 | 2312 | 0.150 |
Why?
|
| Aerosols | 3 | 2000 | 151 | 0.150 |
Why?
|
| Colchicine | 1 | 1997 | 24 | 0.150 |
Why?
|
| Gout Suppressants | 1 | 1997 | 20 | 0.150 |
Why?
|
| Health Behavior | 1 | 2023 | 704 | 0.150 |
Why?
|
| Reference Values | 6 | 2009 | 742 | 0.150 |
Why?
|
| Standard of Care | 1 | 2018 | 62 | 0.150 |
Why?
|
| Kinetics | 21 | 1987 | 1550 | 0.150 |
Why?
|
| Blood Proteins | 10 | 2003 | 232 | 0.140 |
Why?
|
| Partnership Practice | 1 | 2017 | 3 | 0.140 |
Why?
|
| Monocytes | 4 | 1996 | 503 | 0.140 |
Why?
|
| Adaptive Clinical Trials as Topic | 3 | 2021 | 19 | 0.140 |
Why?
|
| Consensus | 4 | 2022 | 535 | 0.140 |
Why?
|
| Climate | 1 | 2017 | 84 | 0.140 |
Why?
|
| Surveys and Questionnaires | 6 | 2015 | 4625 | 0.140 |
Why?
|
| Community Health Services | 1 | 2018 | 212 | 0.140 |
Why?
|
| Arginine | 1 | 2018 | 236 | 0.140 |
Why?
|
| Placebo Effect | 1 | 2017 | 51 | 0.140 |
Why?
|
| Fluocinolone Acetonide | 4 | 2002 | 16 | 0.140 |
Why?
|
| Glutathione | 1 | 2018 | 300 | 0.130 |
Why?
|
| Biopsy | 6 | 2006 | 1040 | 0.130 |
Why?
|
| Lymphocyte Activation | 5 | 2001 | 1044 | 0.130 |
Why?
|
| Patient Outcome Assessment | 1 | 2017 | 121 | 0.130 |
Why?
|
| Intestinal Absorption | 6 | 1987 | 93 | 0.130 |
Why?
|
| Health Services Research | 1 | 2019 | 371 | 0.130 |
Why?
|
| Airway Remodeling | 1 | 2016 | 57 | 0.130 |
Why?
|
| Nasal Mucosa | 1 | 2016 | 93 | 0.130 |
Why?
|
| Hypersensitivity, Immediate | 2 | 2012 | 46 | 0.130 |
Why?
|
| Organizational Case Studies | 1 | 2016 | 69 | 0.130 |
Why?
|
| Eye Diseases | 1 | 2016 | 76 | 0.130 |
Why?
|
| Cerebrovascular Disorders | 1 | 2016 | 82 | 0.130 |
Why?
|
| Hospitals, Pediatric | 1 | 2019 | 479 | 0.130 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2017 | 333 | 0.130 |
Why?
|
| Machine Learning | 1 | 2019 | 318 | 0.130 |
Why?
|
| Metered Dose Inhalers | 4 | 2016 | 14 | 0.130 |
Why?
|
| Ankyrin Repeat | 1 | 2015 | 2 | 0.120 |
Why?
|
| DNA Methylation | 2 | 2016 | 496 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2015 | 27 | 0.120 |
Why?
|
| Research Report | 1 | 2015 | 75 | 0.120 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2015 | 17 | 0.120 |
Why?
|
| Interleukin-4 | 5 | 2015 | 208 | 0.120 |
Why?
|
| Immunization | 2 | 2016 | 401 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2016 | 2099 | 0.120 |
Why?
|
| Oropharynx | 1 | 2015 | 36 | 0.120 |
Why?
|
| Decision Making | 1 | 2021 | 781 | 0.120 |
Why?
|
| Eosinophilia | 1 | 2017 | 186 | 0.120 |
Why?
|
| Family | 1 | 2018 | 591 | 0.120 |
Why?
|
| alpha-N-Acetylgalactosaminidase | 1 | 2014 | 2 | 0.120 |
Why?
|
| Congresses as Topic | 1 | 2016 | 196 | 0.120 |
Why?
|
| Emergency Service, Hospital | 3 | 2020 | 1812 | 0.120 |
Why?
|
| Interferon-alpha | 1 | 2015 | 187 | 0.120 |
Why?
|
| Secondary Prevention | 1 | 2015 | 222 | 0.120 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 583 | 0.120 |
Why?
|
| Text Messaging | 1 | 2016 | 154 | 0.120 |
Why?
|
| Fatty Acid Desaturases | 1 | 2014 | 29 | 0.110 |
Why?
|
| Social Media | 1 | 2016 | 132 | 0.110 |
Why?
|
| Mortality | 1 | 2016 | 288 | 0.110 |
Why?
|
| Integrin beta Chains | 1 | 2013 | 6 | 0.110 |
Why?
|
| Overweight | 1 | 2017 | 471 | 0.110 |
Why?
|
| Aerosol Propellants | 3 | 2002 | 3 | 0.110 |
Why?
|
| Primary Health Care | 2 | 2022 | 1515 | 0.110 |
Why?
|
| Aged | 17 | 2019 | 19094 | 0.110 |
Why?
|
| Metabolic Clearance Rate | 7 | 2004 | 102 | 0.110 |
Why?
|
| DNA, Bacterial | 1 | 2015 | 310 | 0.110 |
Why?
|
| Nuclear Pore Complex Proteins | 1 | 2013 | 31 | 0.110 |
Why?
|
| Saliva | 1 | 2015 | 189 | 0.110 |
Why?
|
| Rhinitis, Allergic, Seasonal | 3 | 2003 | 32 | 0.110 |
Why?
|
| Kv Channel-Interacting Proteins | 1 | 2013 | 3 | 0.110 |
Why?
|
| Sleep Deprivation | 1 | 2015 | 166 | 0.110 |
Why?
|
| Receptors, Purinergic P2X7 | 1 | 2012 | 11 | 0.110 |
Why?
|
| Immunologic Factors | 1 | 2015 | 220 | 0.100 |
Why?
|
| Longitudinal Studies | 5 | 2016 | 2386 | 0.100 |
Why?
|
| Respiration | 2 | 2003 | 179 | 0.100 |
Why?
|
| Europe | 2 | 2018 | 336 | 0.100 |
Why?
|
| Recurrence | 5 | 2016 | 936 | 0.100 |
Why?
|
| Fetal Proteins | 1 | 2012 | 16 | 0.100 |
Why?
|
| Th1 Cells | 1 | 2013 | 123 | 0.100 |
Why?
|
| Quantitative Trait Loci | 2 | 2013 | 307 | 0.100 |
Why?
|
| Rhinitis, Allergic, Perennial | 2 | 2003 | 23 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2019 | 1183 | 0.100 |
Why?
|
| Communication | 1 | 2017 | 747 | 0.100 |
Why?
|
| DNA | 2 | 2015 | 1351 | 0.100 |
Why?
|
| Genomics | 1 | 2016 | 639 | 0.100 |
Why?
|
| Pindolol | 3 | 1991 | 15 | 0.100 |
Why?
|
| Child Behavior Disorders | 2 | 1991 | 131 | 0.100 |
Why?
|
| Dermatitis, Atopic | 1 | 1995 | 307 | 0.100 |
Why?
|
| Methacholine Chloride | 4 | 2003 | 47 | 0.100 |
Why?
|
| Osteoporosis | 3 | 2004 | 226 | 0.100 |
Why?
|
| Pharmacokinetics | 1 | 2011 | 25 | 0.100 |
Why?
|
| Bronchoalveolar Lavage Fluid | 8 | 2003 | 589 | 0.100 |
Why?
|
| T-Box Domain Proteins | 1 | 2012 | 92 | 0.100 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 351 | 0.100 |
Why?
|
| Multicenter Studies as Topic | 2 | 2010 | 249 | 0.100 |
Why?
|
| Skin Tests | 5 | 2015 | 122 | 0.100 |
Why?
|
| Multivariate Analysis | 6 | 2011 | 1435 | 0.100 |
Why?
|
| Radioligand Assay | 4 | 1995 | 43 | 0.090 |
Why?
|
| Interferon-gamma | 3 | 1995 | 722 | 0.090 |
Why?
|
| Gentamicins | 2 | 1982 | 42 | 0.090 |
Why?
|
| Gold | 1 | 1992 | 106 | 0.090 |
Why?
|
| Epidemiologic Studies | 1 | 2011 | 57 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 1178 | 0.090 |
Why?
|
| Histamine | 1 | 1991 | 63 | 0.090 |
Why?
|
| Erythromycin | 3 | 1986 | 24 | 0.090 |
Why?
|
| Eosinophil Granule Proteins | 6 | 2003 | 20 | 0.090 |
Why?
|
| Affective Symptoms | 1 | 1991 | 47 | 0.090 |
Why?
|
| Infant, Newborn | 8 | 2012 | 5035 | 0.090 |
Why?
|
| RNA-Binding Proteins | 1 | 2013 | 344 | 0.090 |
Why?
|
| Models, Biological | 4 | 2008 | 1630 | 0.090 |
Why?
|
| Gene-Environment Interaction | 1 | 2012 | 184 | 0.090 |
Why?
|
| World Health Organization | 1 | 2010 | 103 | 0.090 |
Why?
|
| Interviews as Topic | 2 | 2015 | 582 | 0.090 |
Why?
|
| Respiratory Hypersensitivity | 1 | 1990 | 60 | 0.090 |
Why?
|
| Students | 1 | 2014 | 501 | 0.090 |
Why?
|
| Logistic Models | 6 | 2015 | 1843 | 0.090 |
Why?
|
| Adipokines | 1 | 2010 | 42 | 0.090 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 474 | 0.090 |
Why?
|
| Leukocytes | 2 | 1991 | 277 | 0.090 |
Why?
|
| Absorption | 4 | 2001 | 52 | 0.080 |
Why?
|
| Epinephrine | 1 | 1991 | 164 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 667 | 0.080 |
Why?
|
| Disease Susceptibility | 1 | 2011 | 316 | 0.080 |
Why?
|
| Lectins, C-Type | 1 | 2009 | 61 | 0.080 |
Why?
|
| Receptors, IgE | 1 | 2009 | 40 | 0.080 |
Why?
|
| Genetic Markers | 1 | 2010 | 321 | 0.080 |
Why?
|
| Receptors, Corticotropin-Releasing Hormone | 1 | 2009 | 32 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 347 | 0.080 |
Why?
|
| Child Day Care Centers | 1 | 2009 | 33 | 0.080 |
Why?
|
| Retrospective Studies | 8 | 2023 | 12515 | 0.080 |
Why?
|
| National Health Programs | 1 | 2009 | 20 | 0.080 |
Why?
|
| RNA | 1 | 2015 | 810 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2013 | 647 | 0.080 |
Why?
|
| Health Services | 2 | 2007 | 103 | 0.080 |
Why?
|
| Common Cold | 1 | 2008 | 12 | 0.080 |
Why?
|
| Models, Genetic | 1 | 2011 | 565 | 0.080 |
Why?
|
| Picornaviridae Infections | 1 | 2008 | 30 | 0.080 |
Why?
|
| Superoxides | 1 | 1989 | 214 | 0.080 |
Why?
|
| Cystic Fibrosis | 2 | 2015 | 955 | 0.080 |
Why?
|
| Quality Improvement | 1 | 2016 | 951 | 0.080 |
Why?
|
| Weights and Measures | 1 | 2008 | 7 | 0.080 |
Why?
|
| Interleukin-5 | 2 | 2020 | 30 | 0.080 |
Why?
|
| Bronchial Provocation Tests | 3 | 2019 | 53 | 0.080 |
Why?
|
| Bronchitis | 3 | 2003 | 35 | 0.080 |
Why?
|
| Air Pollution, Indoor | 1 | 2009 | 108 | 0.070 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2008 | 82 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2014 | 601 | 0.070 |
Why?
|
| Aminopyridines | 1 | 2008 | 81 | 0.070 |
Why?
|
| Perception | 2 | 2019 | 311 | 0.070 |
Why?
|
| Gene Expression Profiling | 2 | 2011 | 1521 | 0.070 |
Why?
|
| Benzamides | 1 | 2008 | 169 | 0.070 |
Why?
|
| Administration, Intranasal | 2 | 2001 | 75 | 0.070 |
Why?
|
| Digoxin | 3 | 1977 | 26 | 0.070 |
Why?
|
| Cell Fractionation | 1 | 1987 | 51 | 0.070 |
Why?
|
| Advisory Committees | 2 | 2021 | 208 | 0.070 |
Why?
|
| Binding, Competitive | 3 | 1995 | 193 | 0.070 |
Why?
|
| Insurance, Health | 1 | 2009 | 244 | 0.070 |
Why?
|
| Cosyntropin | 2 | 2005 | 4 | 0.070 |
Why?
|
| Income | 1 | 2008 | 167 | 0.070 |
Why?
|
| Adrenal Glands | 3 | 1997 | 67 | 0.070 |
Why?
|
| Family Characteristics | 1 | 2008 | 152 | 0.070 |
Why?
|
| Cough | 1 | 2007 | 107 | 0.070 |
Why?
|
| Safety | 2 | 2019 | 297 | 0.070 |
Why?
|
| Receptors, Interleukin-2 | 2 | 1997 | 64 | 0.070 |
Why?
|
| Dietary Supplements | 1 | 2010 | 460 | 0.070 |
Why?
|
| Periodicals as Topic | 1 | 2009 | 181 | 0.070 |
Why?
|
| Proteins | 1 | 2012 | 912 | 0.070 |
Why?
|
| Chromatography, High Pressure Liquid | 7 | 2008 | 472 | 0.070 |
Why?
|
| Animals, Domestic | 2 | 2004 | 11 | 0.070 |
Why?
|
| Demography | 1 | 2007 | 262 | 0.070 |
Why?
|
| Stress, Psychological | 1 | 2014 | 944 | 0.070 |
Why?
|
| Pharmaceutical Preparations | 2 | 2011 | 168 | 0.070 |
Why?
|
| Inflammation Mediators | 3 | 2003 | 476 | 0.070 |
Why?
|
| Lipopolysaccharides | 1 | 1989 | 812 | 0.060 |
Why?
|
| Mucus | 1 | 1986 | 54 | 0.060 |
Why?
|
| Anticonvulsants | 1 | 1987 | 178 | 0.060 |
Why?
|
| Tissue Distribution | 3 | 2001 | 285 | 0.060 |
Why?
|
| Isoproterenol | 2 | 1991 | 102 | 0.060 |
Why?
|
| Tosyl Compounds | 1 | 2005 | 14 | 0.060 |
Why?
|
| Child Behavior | 1 | 1987 | 220 | 0.060 |
Why?
|
| Adiposity | 1 | 2010 | 457 | 0.060 |
Why?
|
| Interleukin-2 | 3 | 1997 | 417 | 0.060 |
Why?
|
| Eosinophil Cationic Protein | 1 | 2005 | 9 | 0.060 |
Why?
|
| Interleukin-13 | 2 | 2015 | 122 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 1727 | 0.060 |
Why?
|
| Mice | 2 | 2019 | 14916 | 0.060 |
Why?
|
| Food Hypersensitivity | 1 | 2009 | 253 | 0.060 |
Why?
|
| Life Style | 1 | 2007 | 430 | 0.060 |
Why?
|
| Area Under Curve | 3 | 2016 | 275 | 0.060 |
Why?
|
| Hormones | 1 | 2005 | 133 | 0.060 |
Why?
|
| Candidiasis, Oral | 1 | 2004 | 16 | 0.060 |
Why?
|
| Respiratory System | 2 | 2004 | 137 | 0.060 |
Why?
|
| Cataract | 2 | 2003 | 185 | 0.060 |
Why?
|
| Metalloendopeptidases | 1 | 2004 | 55 | 0.060 |
Why?
|
| Emergency Medical Services | 1 | 2011 | 587 | 0.060 |
Why?
|
| Smoking Cessation | 1 | 2008 | 374 | 0.060 |
Why?
|
| Cell Count | 4 | 2005 | 305 | 0.060 |
Why?
|
| Analysis of Variance | 4 | 2015 | 1226 | 0.060 |
Why?
|
| ADAM Proteins | 1 | 2004 | 58 | 0.060 |
Why?
|
| Ecchymosis | 1 | 2003 | 2 | 0.060 |
Why?
|
| Glaucoma | 2 | 2003 | 202 | 0.060 |
Why?
|
| Learning | 1 | 1987 | 352 | 0.060 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2003 | 27 | 0.060 |
Why?
|
| Powders | 2 | 2005 | 38 | 0.050 |
Why?
|
| Histamine Antagonists | 1 | 2003 | 20 | 0.050 |
Why?
|
| Hygiene | 1 | 2003 | 27 | 0.050 |
Why?
|
| Bone Development | 1 | 2003 | 47 | 0.050 |
Why?
|
| Quinidine | 1 | 1982 | 6 | 0.050 |
Why?
|
| Mast Cells | 1 | 2003 | 117 | 0.050 |
Why?
|
| Auranofin | 2 | 1992 | 9 | 0.050 |
Why?
|
| Data Collection | 1 | 2005 | 622 | 0.050 |
Why?
|
| Self Administration | 2 | 2019 | 123 | 0.050 |
Why?
|
| Social Class | 1 | 2003 | 204 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2021 | 59 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2005 | 604 | 0.050 |
Why?
|
| Pregnadienediols | 1 | 2001 | 2 | 0.050 |
Why?
|
| Wakefulness | 1 | 2002 | 128 | 0.050 |
Why?
|
| Bone and Bones | 1 | 2004 | 278 | 0.050 |
Why?
|
| Milk, Human | 1 | 1983 | 128 | 0.050 |
Why?
|
| Protein Binding | 8 | 2004 | 1897 | 0.050 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2006 | 331 | 0.050 |
Why?
|
| Drug Evaluation | 2 | 1999 | 77 | 0.050 |
Why?
|
| Quality of Health Care | 1 | 2006 | 573 | 0.050 |
Why?
|
| Substance-Related Disorders | 2 | 1992 | 947 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2015 | 954 | 0.050 |
Why?
|
| Solutions | 2 | 1997 | 146 | 0.050 |
Why?
|
| Infant, Premature | 2 | 2006 | 478 | 0.050 |
Why?
|
| Life Change Events | 1 | 2022 | 135 | 0.050 |
Why?
|
| Social Behavior | 1 | 2003 | 268 | 0.050 |
Why?
|
| Dosage Forms | 2 | 1995 | 10 | 0.050 |
Why?
|
| Vocal Cord Dysfunction | 1 | 2020 | 7 | 0.050 |
Why?
|
| Infant, Premature, Diseases | 1 | 1982 | 89 | 0.040 |
Why?
|
| Psychology, Adolescent | 1 | 2000 | 63 | 0.040 |
Why?
|
| Biomedical Technology | 1 | 2021 | 40 | 0.040 |
Why?
|
| ROC Curve | 3 | 2010 | 445 | 0.040 |
Why?
|
| Acute Disease | 2 | 2020 | 912 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2001 | 503 | 0.040 |
Why?
|
| Regression Analysis | 4 | 2008 | 946 | 0.040 |
Why?
|
| Alleles | 2 | 2013 | 791 | 0.040 |
Why?
|
| Social Support | 1 | 2003 | 528 | 0.040 |
Why?
|
| Infusions, Intravenous | 3 | 1992 | 372 | 0.040 |
Why?
|
| Government Programs | 1 | 1999 | 22 | 0.040 |
Why?
|
| Muscle, Smooth | 2 | 2015 | 144 | 0.040 |
Why?
|
| Drug Utilization | 2 | 2012 | 167 | 0.040 |
Why?
|
| Pulmonologists | 1 | 2019 | 16 | 0.040 |
Why?
|
| Respiratory Rate | 1 | 2019 | 18 | 0.040 |
Why?
|
| Remission Induction | 1 | 2019 | 233 | 0.040 |
Why?
|
| Immunoglobulin Variable Region | 1 | 1999 | 72 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2019 | 160 | 0.040 |
Why?
|
| Allergists | 1 | 2019 | 19 | 0.040 |
Why?
|
| Drug Substitution | 1 | 2019 | 46 | 0.040 |
Why?
|
| Housing | 1 | 2020 | 114 | 0.040 |
Why?
|
| Rhinitis | 1 | 2020 | 128 | 0.040 |
Why?
|
| Cell Separation | 2 | 1991 | 292 | 0.040 |
Why?
|
| Psychological Tests | 2 | 2008 | 120 | 0.040 |
Why?
|
| Oximetry | 1 | 2019 | 81 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2001 | 296 | 0.040 |
Why?
|
| Goals | 1 | 2019 | 149 | 0.040 |
Why?
|
| Centrifugation | 2 | 1989 | 31 | 0.040 |
Why?
|
| Case-Control Studies | 4 | 2012 | 3005 | 0.040 |
Why?
|
| Statistics, Nonparametric | 3 | 2005 | 386 | 0.040 |
Why?
|
| Immunity, Cellular | 2 | 1998 | 248 | 0.040 |
Why?
|
| Ornithine | 1 | 2018 | 18 | 0.040 |
Why?
|
| Cells, Cultured | 5 | 1997 | 3890 | 0.040 |
Why?
|
| Neutrophils | 3 | 2017 | 1163 | 0.040 |
Why?
|
| Kidney | 3 | 1981 | 1184 | 0.040 |
Why?
|
| Asia | 1 | 2018 | 53 | 0.040 |
Why?
|
| Forced Expiratory Flow Rates | 1 | 1997 | 12 | 0.040 |
Why?
|
| Single-Blind Method | 3 | 2004 | 258 | 0.040 |
Why?
|
| Anuria | 1 | 1977 | 4 | 0.040 |
Why?
|
| Gastroesophageal Reflux | 1 | 2020 | 234 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1999 | 309 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 1080 | 0.040 |
Why?
|
| Dyspnea | 1 | 2019 | 213 | 0.040 |
Why?
|
| Injections, Intravenous | 3 | 1990 | 201 | 0.040 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2020 | 200 | 0.040 |
Why?
|
| North America | 1 | 2018 | 257 | 0.040 |
Why?
|
| Body Mass Index | 2 | 2017 | 1958 | 0.030 |
Why?
|
| Netherlands | 1 | 2016 | 64 | 0.030 |
Why?
|
| Adrenergic beta-1 Receptor Agonists | 1 | 2016 | 5 | 0.030 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2018 | 117 | 0.030 |
Why?
|
| Collagen | 1 | 1998 | 415 | 0.030 |
Why?
|
| Pulmonary Alveoli | 1 | 1999 | 372 | 0.030 |
Why?
|
| Cognition | 1 | 2003 | 989 | 0.030 |
Why?
|
| Patient Care Management | 1 | 2016 | 53 | 0.030 |
Why?
|
| Hospitalists | 1 | 2019 | 174 | 0.030 |
Why?
|
| Infant, Newborn, Diseases | 1 | 1977 | 104 | 0.030 |
Why?
|
| Dust | 2 | 2011 | 84 | 0.030 |
Why?
|
| Focus Groups | 1 | 2017 | 385 | 0.030 |
Why?
|
| Metaproterenol | 1 | 1995 | 2 | 0.030 |
Why?
|
| In Vitro Techniques | 2 | 1996 | 1013 | 0.030 |
Why?
|
| Heart Rate | 1 | 2019 | 704 | 0.030 |
Why?
|
| Infusions, Parenteral | 2 | 1985 | 36 | 0.030 |
Why?
|
| Biotransformation | 4 | 1987 | 49 | 0.030 |
Why?
|
| Phenytoin | 2 | 1987 | 13 | 0.030 |
Why?
|
| Phenobarbital | 2 | 1987 | 17 | 0.030 |
Why?
|
| Core Binding Factor Alpha 3 Subunit | 1 | 2015 | 5 | 0.030 |
Why?
|
| Culture Media | 1 | 1995 | 155 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2015 | 1370 | 0.030 |
Why?
|
| Education | 1 | 2015 | 95 | 0.030 |
Why?
|
| Excipients | 1 | 1995 | 49 | 0.030 |
Why?
|
| Pseudomonas | 1 | 2015 | 26 | 0.030 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2015 | 22 | 0.030 |
Why?
|
| Fever | 1 | 2016 | 279 | 0.030 |
Why?
|
| Enterobacteriaceae | 1 | 2015 | 32 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2015 | 69 | 0.030 |
Why?
|
| Actigraphy | 1 | 2015 | 74 | 0.030 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2015 | 155 | 0.030 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2015 | 32 | 0.030 |
Why?
|
| Staphylococcus | 1 | 2015 | 69 | 0.030 |
Why?
|
| Algorithms | 2 | 2012 | 1468 | 0.030 |
Why?
|
| Costa Rica | 1 | 2014 | 16 | 0.030 |
Why?
|
| Portraits as Topic | 1 | 2014 | 2 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 1999 | 689 | 0.030 |
Why?
|
| Tablets | 2 | 1985 | 36 | 0.030 |
Why?
|
| Particle Size | 1 | 1995 | 317 | 0.030 |
Why?
|
| F-Box Proteins | 1 | 2014 | 20 | 0.030 |
Why?
|
| Receptors, Immunologic | 1 | 2015 | 201 | 0.030 |
Why?
|
| Random Allocation | 2 | 2000 | 335 | 0.030 |
Why?
|
| Forecasting | 1 | 2015 | 331 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2015 | 481 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 6350 | 0.030 |
Why?
|
| Interferon Regulatory Factor-2 | 1 | 2013 | 4 | 0.030 |
Why?
|
| STAT4 Transcription Factor | 1 | 2013 | 4 | 0.030 |
Why?
|
| Health Education | 1 | 2016 | 324 | 0.030 |
Why?
|
| Pseudomonas Infections | 1 | 2015 | 184 | 0.030 |
Why?
|
| Cytosol | 1 | 1994 | 208 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 2015 | 354 | 0.030 |
Why?
|
| Nuclear Pore | 1 | 2012 | 14 | 0.030 |
Why?
|
| Chemistry, Pharmaceutical | 2 | 2004 | 98 | 0.030 |
Why?
|
| Sensitivity and Specificity | 3 | 2004 | 1691 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2020 | 889 | 0.030 |
Why?
|
| Interleukin-12 | 1 | 2013 | 110 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2019 | 896 | 0.030 |
Why?
|
| Tryptases | 2 | 2003 | 10 | 0.030 |
Why?
|
| Bronchoconstrictor Agents | 2 | 2003 | 14 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 2269 | 0.030 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2012 | 26 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2015 | 350 | 0.030 |
Why?
|
| Phytohemagglutinins | 1 | 1992 | 27 | 0.030 |
Why?
|
| Depression, Chemical | 1 | 1992 | 22 | 0.030 |
Why?
|
| Vitamin D Deficiency | 1 | 2014 | 158 | 0.020 |
Why?
|
| Hydroxychloroquine | 1 | 1992 | 55 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 728 | 0.020 |
Why?
|
| Serine Endopeptidases | 2 | 2003 | 102 | 0.020 |
Why?
|
| Inactivation, Metabolic | 1 | 2011 | 11 | 0.020 |
Why?
|
| Exercise | 1 | 2022 | 1644 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 1992 | 117 | 0.020 |
Why?
|
| Basement Membrane | 2 | 2003 | 30 | 0.020 |
Why?
|
| Quinolones | 1 | 1992 | 97 | 0.020 |
Why?
|
| Cockroaches | 1 | 2011 | 21 | 0.020 |
Why?
|
| Canada | 1 | 2012 | 322 | 0.020 |
Why?
|
| Desensitization, Immunologic | 1 | 1992 | 117 | 0.020 |
Why?
|
| Poverty Areas | 1 | 2011 | 32 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2011 | 245 | 0.020 |
Why?
|
| Intelligence Tests | 1 | 1991 | 59 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 1994 | 554 | 0.020 |
Why?
|
| Chlamydophila pneumoniae | 1 | 2010 | 11 | 0.020 |
Why?
|
| Atropine Derivatives | 1 | 1990 | 1 | 0.020 |
Why?
|
| Functional Residual Capacity | 1 | 2010 | 7 | 0.020 |
Why?
|
| Staphylococcal Infections | 1 | 2015 | 336 | 0.020 |
Why?
|
| Pain | 1 | 2016 | 710 | 0.020 |
Why?
|
| Parasympatholytics | 1 | 1990 | 13 | 0.020 |
Why?
|
| Genetic Complementation Test | 1 | 2010 | 62 | 0.020 |
Why?
|
| Methacholine Compounds | 1 | 1990 | 2 | 0.020 |
Why?
|
| Mycoplasma pneumoniae | 1 | 2010 | 28 | 0.020 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2012 | 235 | 0.020 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2010 | 36 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2011 | 176 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2010 | 797 | 0.020 |
Why?
|
| Health | 1 | 2010 | 74 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 1991 | 225 | 0.020 |
Why?
|
| Transcription Factors | 1 | 1998 | 1528 | 0.020 |
Why?
|
| Rabbits | 5 | 1991 | 736 | 0.020 |
Why?
|
| Reference Standards | 1 | 2010 | 159 | 0.020 |
Why?
|
| Drug Synergism | 2 | 2001 | 316 | 0.020 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2010 | 117 | 0.020 |
Why?
|
| Gene Expression | 2 | 2010 | 1420 | 0.020 |
Why?
|
| Dialysis | 2 | 1986 | 17 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1989 | 76 | 0.020 |
Why?
|
| Base Sequence | 1 | 2013 | 2118 | 0.020 |
Why?
|
| Free Radicals | 1 | 1989 | 99 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 1991 | 482 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 1973 | 487 | 0.020 |
Why?
|
| Cats | 2 | 1999 | 193 | 0.020 |
Why?
|
| Emergencies | 1 | 2009 | 146 | 0.020 |
Why?
|
| Carbamazepine | 1 | 1987 | 18 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 994 | 0.020 |
Why?
|
| Iodocyanopindolol | 1 | 1987 | 11 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 2321 | 0.020 |
Why?
|
| Propranolol | 1 | 1987 | 49 | 0.020 |
Why?
|
| Body Weight | 1 | 2011 | 869 | 0.020 |
Why?
|
| Iodine Radioisotopes | 1 | 1987 | 126 | 0.020 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2006 | 29 | 0.020 |
Why?
|
| Lung Volume Measurements | 1 | 2006 | 45 | 0.020 |
Why?
|
| Cell Survival | 1 | 1989 | 1021 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 1989 | 1233 | 0.020 |
Why?
|
| Plethysmography | 1 | 2006 | 104 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2008 | 413 | 0.020 |
Why?
|
| Creatinine | 3 | 1977 | 424 | 0.020 |
Why?
|
| Gastric Emptying | 1 | 1985 | 40 | 0.020 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2006 | 66 | 0.020 |
Why?
|
| Nicotine | 1 | 2008 | 265 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2010 | 876 | 0.020 |
Why?
|
| Phenylcarbamates | 1 | 2005 | 3 | 0.020 |
Why?
|
| Aminophylline | 1 | 1985 | 5 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2008 | 562 | 0.020 |
Why?
|
| Interleukin-1 | 1 | 1989 | 966 | 0.020 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1987 | 159 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2006 | 623 | 0.010 |
Why?
|
| Methylprednisolone Hemisuccinate | 1 | 1984 | 3 | 0.010 |
Why?
|
| Galvanic Skin Response | 1 | 2004 | 26 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1989 | 1134 | 0.010 |
Why?
|
| Blood Cells | 1 | 2003 | 38 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1987 | 680 | 0.010 |
Why?
|
| Contraceptives, Oral, Combined | 1 | 1983 | 16 | 0.010 |
Why?
|
| Contraceptives, Oral | 1 | 1983 | 25 | 0.010 |
Why?
|
| Age Distribution | 1 | 2004 | 339 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2010 | 2557 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2004 | 335 | 0.010 |
Why?
|
| Personality | 1 | 1984 | 113 | 0.010 |
Why?
|
| Indoles | 1 | 2005 | 306 | 0.010 |
Why?
|
| Cell Division | 2 | 1997 | 759 | 0.010 |
Why?
|
| Equipment Design | 1 | 2004 | 508 | 0.010 |
Why?
|
| Perfusion | 2 | 1981 | 145 | 0.010 |
Why?
|
| Preventive Health Services | 1 | 2004 | 135 | 0.010 |
Why?
|
| Life Tables | 1 | 2002 | 17 | 0.010 |
Why?
|
| Sulfonamides | 1 | 2005 | 445 | 0.010 |
Why?
|
| Colitis, Ulcerative | 1 | 1983 | 105 | 0.010 |
Why?
|
| Headache | 1 | 1982 | 132 | 0.010 |
Why?
|
| Outpatients | 1 | 2004 | 327 | 0.010 |
Why?
|
| Smoking Prevention | 1 | 2002 | 157 | 0.010 |
Why?
|
| Probability | 1 | 2002 | 291 | 0.010 |
Why?
|
| Therapeutic Equivalency | 1 | 2000 | 18 | 0.010 |
Why?
|
| Receptors, Adrenergic | 1 | 1981 | 35 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 2001 | 108 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 2000 | 168 | 0.010 |
Why?
|
| Urea | 2 | 1991 | 68 | 0.010 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1982 | 278 | 0.010 |
Why?
|
| Alternaria | 1 | 1999 | 8 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 1982 | 219 | 0.010 |
Why?
|
| p-Aminohippuric Acid | 1 | 1979 | 6 | 0.010 |
Why?
|
| Inulin | 1 | 1979 | 6 | 0.010 |
Why?
|
| Renal Veins | 1 | 1979 | 9 | 0.010 |
Why?
|
| Crohn Disease | 1 | 1983 | 196 | 0.010 |
Why?
|
| Infusions, Intra-Arterial | 1 | 1979 | 46 | 0.010 |
Why?
|
| Physiology | 1 | 1999 | 9 | 0.010 |
Why?
|
| Renal Artery | 1 | 1979 | 25 | 0.010 |
Why?
|
| Isomerism | 1 | 1999 | 43 | 0.010 |
Why?
|
| Superantigens | 1 | 1999 | 69 | 0.010 |
Why?
|
| Depression | 1 | 1987 | 1133 | 0.010 |
Why?
|
| Liver | 2 | 1984 | 1631 | 0.010 |
Why?
|
| Lissamine Green Dyes | 1 | 1998 | 1 | 0.010 |
Why?
|
| Methylation | 1 | 1979 | 208 | 0.010 |
Why?
|
| Equipment Failure | 1 | 1999 | 106 | 0.010 |
Why?
|
| Azo Compounds | 1 | 1998 | 25 | 0.010 |
Why?
|
| Coloring Agents | 1 | 1998 | 72 | 0.010 |
Why?
|
| Dogs | 1 | 1999 | 334 | 0.010 |
Why?
|
| Mucous Membrane | 1 | 1998 | 108 | 0.010 |
Why?
|
| Gestational Age | 1 | 1980 | 759 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1997 | 319 | 0.010 |
Why?
|
| Statistics as Topic | 2 | 1991 | 294 | 0.010 |
Why?
|
| Aortic Coarctation | 1 | 1977 | 69 | 0.010 |
Why?
|
| Fibrosis | 1 | 1998 | 453 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 1998 | 449 | 0.010 |
Why?
|
| Mothers | 1 | 2000 | 651 | 0.010 |
Why?
|
| Rats | 2 | 1981 | 4943 | 0.010 |
Why?
|
| Species Specificity | 2 | 1986 | 545 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1995 | 293 | 0.010 |
Why?
|
| Arteriosclerosis | 1 | 1973 | 82 | 0.010 |
Why?
|
| Gout | 1 | 1973 | 37 | 0.010 |
Why?
|
| Nervous System | 1 | 1992 | 63 | 0.010 |
Why?
|
| 17-Hydroxycorticosteroids | 1 | 1992 | 1 | 0.010 |
Why?
|
| Ipratropium | 1 | 1992 | 6 | 0.010 |
Why?
|
| Cell Line | 1 | 1997 | 2639 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 1999 | 2763 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 1973 | 211 | 0.010 |
Why?
|
| Positive-Pressure Respiration | 1 | 1992 | 68 | 0.010 |
Why?
|
| Coronary Disease | 1 | 1973 | 347 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 1997 | 1314 | 0.010 |
Why?
|
| Epithelium | 1 | 1991 | 297 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 1989 | 173 | 0.010 |
Why?
|
| Respiratory Insufficiency | 1 | 1992 | 291 | 0.000 |
Why?
|
| Receptors, Steroid | 1 | 1986 | 47 | 0.000 |
Why?
|
| Fluorescence Polarization | 1 | 1986 | 35 | 0.000 |
Why?
|
| Disposable Equipment | 1 | 1986 | 15 | 0.000 |
Why?
|
| Drug Stability | 1 | 1986 | 151 | 0.000 |
Why?
|
| Blood Specimen Collection | 1 | 1986 | 31 | 0.000 |
Why?
|
| Capillaries | 1 | 1986 | 91 | 0.000 |
Why?
|
| Heart Failure | 1 | 1977 | 1952 | 0.000 |
Why?
|
| Hydrolysis | 1 | 1984 | 175 | 0.000 |
Why?
|
| Transcortin | 1 | 1983 | 14 | 0.000 |
Why?
|
| Aspartate Aminotransferases | 1 | 1983 | 86 | 0.000 |
Why?
|
| Alanine Transaminase | 1 | 1983 | 141 | 0.000 |
Why?
|
| Radioimmunoassay | 1 | 1974 | 163 | 0.000 |
Why?
|
| Computers | 1 | 1974 | 60 | 0.000 |
Why?
|